Browse All

Current Filters

CLEAR FILTER x

TITLE

A Phase 1, Open-label, Single Center Study of KYV-101, an Autologous Fully-human Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects with Non-relapsing and Progressive Forms of Multiple Sclerosis

Comparing Brain MRI-derived Whole Brain and Grey Matter Volumes with Patient Reported Outcomes in a Cohort of People Living with MS